AMGN: Revenue grew 8%, while product momentum offset biosimilar and pricing pressure

What happened

Amgen reported third-quarter revenue of $10.4 billion, up 8%, with higher GAAP and non-GAAP earnings per share. Seventeen products recorded double-digit growth. The company provided fiscal-year revenue guidance of $38.9 billion to $39.7 billion and said biosimilar competition and U.S. pricing policy weigh on selected products.

Confirmed

Global impact / market context

Growth across 17 products suggests several medicines are contributing to sales, while competition from similar medicines and U.S. pricing policy may limit revenue from selected products. This tension could affect earnings and the company’s ability to deliver within its stated revenue guidance.

Analyst inference

The report combines rising revenue and earnings per share with pressures from competitors and pricing policy. The revenue guidance provides a benchmark for judging future results, but the supplied information does not show whether product growth will continue or how much pressure will offset it.

Analyst inference

What to watch

1. Compare later quarterly revenue and earnings per share with the reported 8% revenue growth and higher earnings to assess whether strength across products continues. Analyst inference
2. Watch for updates to the company’s revenue guidance of $38.9 billion to $39.7 billion, which would indicate whether management expects its outlook to change. Analyst inference
3. Look for further information about biosimilar competition and U.S. pricing policy affecting selected products, since either could constrain their sales or prices. Analyst inference

Evidence

• Original source link unavailable